Skip to main content
. 2023 Jan 16;12(1):186–193. doi: 10.21037/tcr-22-2060

Table 1. Findings of gene sequencing during treatment.

Time of sampling Method Sample Gene Mutation style Frequency or CN
Before using EGFR-TKI 8-gene panel NGS FFPE EGFR Exon 19 deletion 14.85%
After using gefitinib ddPCR cfDNA (liquid biopsy) EGFR Exon 20 T790M (−)
9-gene panel NGS cfDNA (liquid biopsy) EGFR Exon 19 deletion 1.6%
TP53 p.K132R 0.64%
After using bevacizumab + carboplatin + pemetrexed 56-gene panel NGS FFPE EGFR Exon 19 deletion 26.02%
TP53 p.K132R 51.12%
EGFR Amplification CN =15.48
mTOR p.G28V 62.79%
BRCA2 p.E2355K 70.17%
After using bevacizumab + sindilimab 9-gene panel NGS cfDNA (liquid biopsy) EGFR Exon 19 deletion 8.2%
Exon 20 T790M (+) 11.6%
TP53 p.K132R 1.7%
After using osimertinib 1021-gene panel NGS FFPE+ blood TMB 3.84 Muts/Mb
MSI MSS
EGFR Exon19 deletion 30.8%
Exon 20 T790M (+) 14.1%
BRAF BTN2A1-BRAF fusion 9.1%
TP53 p.K132R 30%
TGFBR1 p.D104Y 12.8%
MYC Amplification CN =7.4
FANCG Amplification CN =6.8
IHC FFPE PD-L1 PD-L1 (+) 90%

CN, copy number; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NGS, next generation sequencing; FFPE, formaldehyde fixed paraffin embedded; ddPCR, droplet digital polymerase chain reaction; cfDNA, cell free DNA; TMB, tumor mutational burden; MSI, microsatellite instability; MSS, microsatellite stability; IHC, immunohistochemistry; PD-L1, programmed cell death-ligand 1.